T cell‐inflamed gene expression profile is associated with favorable disease‐specific survival in non‐hypermutated microsatellite‐stable colorectal cancer patients
Authors:
Open Access
- 7 November 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (6) , 6583-6593
Abstract
Background: The anti‐tumor immune response plays a key role in colorectal cancer (CRC) progression and survival. The T cell‐inflamed gene expression profile (GEP) is a biomarker predicting response to checkpoint inhibitor immunotherapy across immunogenic cancer types, but the prognostic value in CRC is unknown. We evaluated associations with disease‐specific survival, somatic mutations, and examined its differentially expressed genes and pathways among 84 sporadic CRC patients from the Seattle Colon Cancer Family Registry.Methods: Gene expression profiling was performed using Nanostring's nCounter PanCancer IO 360 panel. Somatic mutations were identified by a targeted DNA sequencing panel.Results: The T cell‐inflamed GEP was positively associated with tumor mutation burden and microsatellite instability high (MSI‐H). Higher T cell‐inflamed GEP had favorable CRC‐specific survival (hazard ratio [HR] per standard deviation unit = 0.50, p = 0.004) regardless of hypermutation or MSI status. Analysis of recurrently mutated genes having at least 10 mutation carriers, suggested that the T cell‐inflamed GEP is positively associated with RYR1, and negatively associated with APC. However, these associations were attenuated after adjusting for hypermutation or MSI status. We also found that expression of genes RPL23, EPCAM, AREG and ITGA6, and the Wnt signaling pathway was negatively associated with the T cell‐inflamed GEP, which might indicate immune‐inhibitory mechanisms.Conclusions: Our results show that the T cell‐inflamed GEP is a prognostic biomarker in non‐hypermutated microsatellite‐stable CRC. This also suggests that patient stratification for immunotherapy within this CRC subgroup should be explored further. Moreover, reported immune‐inhibitory gene expression signals may suggest targets for therapeutic combination with immunotherapy.Keywords
Funding Information
- Fred Hutchinson Cancer Center (P30 CA015704)
- National Cancer Institute (K05CA142885, P20CA252733, R01CA076366, R01CA107333, R01CA118699, R01CA189532, R01CA248857, R21CA230486, U01CA137088, U01CA167551, U01CA74794)
This publication has 46 references indexed in Scilit:
- Gain of function of the immune system caused by a ryanodine receptor 1 mutationJournal of Cell Science, 2013
- Regulation of Amphiregulin Gene Expression by β-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR SystemPLOS ONE, 2012
- Nuclear signalling by tumour-associated antigen EpCAMNature Cell Biology, 2009
- Differential expression of the integrins α6Aβ4 and α6Bβ4 along the crypt–villus axis in the human small intestineHistochemistry and Cell Biology, 2008
- Differential Wnt Pathway Gene Expression and E-Cadherin Truncation in Sporadic Colorectal Cancers with and without Microsatellite InstabilityClinical Cancer Research, 2008
- Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon CancerCancer Epidemiology, Biomarkers & Prevention, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- The control of the false discovery rate in multiple testing under dependencyThe Annals of Statistics, 2001
- Tumor Microsatellite Instability and Clinical Outcome in Young Patients with Colorectal CancerNew England Journal of Medicine, 2000